gip glp 1 agonist tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 SEMA vs TIRZ vs RETA

Gallbladder Problems: Including gallstones and cholecystitis (inflammation of the gallbladder)

We first asked participants whether they thought the growing popularity of GLP-1 drugs will change Americans dietary preferences and food purchasing habits

Garcia-Perez L-E, Maldonado JM, Ranta KT, Raha S

[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Kukla A, Hill J, Merzkani M, et al

International coverage policies vary significantly

No study has asked the broader question: do GLP-1s work against substance use disorders across the board, and can they reduce the serious harms of addiction, including overdose and drug-related death